iBET’s Advanced Bioanalytics R&D Presented at Gene and Cell Therapies 2025 in Munich
June 11, 2025
iBET Latest Research on AAV and HCP Characterization
iBET scientist Sofia Carvalho participated in the 4th Gene and Cell Therapies conference- CMC, CGT & Vector Manufacturing Summit, held June 04-05, in Munich, Germany.
The Gene and Cell Therapies conference is dedicated to accelerating progress in CMC and quality development of gene and cell therapy (GCT) products.
Sofia Carvalho delivered an oral communication on” Unveiling AAV Quality Attributes and HCP Profiling using Advanced Bioanalytics for Bioprocess Characterization”. This study included:
- Viral proteins (VP) identity analysis by Mass Spectrometry (MS) and Capillary Electrophoresis methods;
- AAV capsid Post Translational Modifications assessment using an MS based multi-attribute method (MAM) workflow;
- Host Cell Protein (HCP) profiling using MS;
- Study of how bioprocess parameters affect HCP levels and capsid Critical Quality Attributes.
Congratulations to Sofia for once again sharing iBET’s advancements on bioanalytics with the scientific international community.
